  This review summarizes the current management of heart<symptom> failure<symptom> ( HF) in patients with reduced ejection fraction and the potential role of heart rate lowering agents in select populations , as recommended in the updated guidelines. Areas covered: PubMed was searched for studies that evaluated the role of heart rate lowering or ivabradine in HF management. Expert commentary: Targeting heart rate may offer benefit when added to renin-angiotensin aldosterone antagonists , and beta-blockers. Ivabradine is a heart rate lowering agent that acts on the funny current ( I